Eli Lilly Receives Validation of Its Anti-Obesity Drug in Europe

Eli Lilly makes progress with its new drug. The American pharmaceutical company has announced that the Committee for Medicinal Products for Human Use (Chmp) of the European Medicines Agency (EMA) has issued a positive opinion recommending the authorization of tirzepatide for weight control in adults with obesity or overweight. Specifically, the drug is indicated as a complement to diet and exercise.

The pharmaceutical company has considered that this decision is a “fundamental” regulatory step for the final approval of its drug. In any case, following this positive opinion, the European Commission (EC) is expected to make a final decision on the marketing authorization of the weight control drug in the coming months.

Miriam Rubio Santos, medical director of diabetes and obesity area at Eli Lilly Spain, has assured that “tirzepatide is a prescription medication and is the first and only treatment that activates the GIP and GLP-1 hormone receptors.” The directive added that “ obesity is a chronic and progressive disease that requires a multidisciplinary approach, whose treatment may include behavioral therapy, diet, exercise, pharmacological or surgical treatment.”

Read more about Eli Lilly and the validation in Europe of its drug against obesity, and find the most important financial news from around the world with our companion app Born2Invest.

Eli Lilly expects the European Commission to make a final decision on marketing authorization for the drug in the coming months

Specifically, this drug has marketing authorization in the European Union (EU) for the treatment of adults with insufficiently controlled type 2 diabetes as a complement to diet and exercise. In this case, the CHMP’s positive opinion has been based on the results of a phase III clinical trial.

The American pharmaceutical company Eli Lilly increased its profits by 85% in the first half of the year, up to 1,763 million dollars, boosted by its anti-diabetes drugs Mounjaro, Verzenio, Jardiance, and Taltz, in addition to the sale of 579 million dollars from the sale of Baqsimi’s rights. In fact, with the development of the results, the company improved its outlook, to a  revenue range of between $33.4 billion and $33.9 billion by the end of the year, compared to $31 billion previously.

Eli Lilly unites healthcare and research to create medicines that improve the lives of people around the world. Harnessing the power of biotechnology, chemistry, and genetics, its scientists are advancing new findings to solve some of the world’s most important health challenges, redefining diabetes care, treating obesity, and reducing its most devastating effects in the long term.

__

(Featured image by TotalShape via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.